Similar articles

• Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.

  Nowrousian MR, Dunst J, Vaupel P. Nowrousian MR, et al. Strahlenther Onkol. 2008 Mar;184(3):121-36. doi: 10.1007/s00066-008-1841-3. Strahlenther Onkol. 2008. PMID: 18330508 Review.
• Clarifying the use of erythropoietic agents.

  Smith RE Jr. Smith RE Jr. J Support Oncol. 2004 May-Jun;2(3):200, 202; author reply 202. J Support Oncol. 2004. PMID: 15328822 No abstract available.
• Erythropoietin therapy in cancer-related anaemia, yes or no?

  Herrmann R. Herrmann R. Intern Med J. 2008 Oct;38(10):749-50. doi: 10.1111/j.1445-5994.2008.01767.x. Intern Med J. 2008. PMID: 19143876 No abstract available.
• Cancer- and treatment-related anemia.

  Rodgers GM 3rd, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Demetri GD, Djulbegovic B, Garst JL, Gore M, Kraut EH, Lin WC, Millenson M, Mock V, Reinke D, Rosenthal J, Sabbatini P. Rodgers GM 3rd, et al. J Natl Compr Canc Netw. 2005 Nov;3(6):772-89. doi: 10.6004/jnccn.2005.0046. J Natl Compr Canc Netw. 2005. PMID: 16316613 No abstract available.
• Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms.

  Hadland BK, Longmore GD. Hadland BK, et al. J Clin Oncol. 2009 Sep 1;27(25):4217-26. doi: 10.1200/JCO.2008.21.6945. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636005 Review.